Research: Survodutide

Dual GLP-1/glucagon agonist in development

Survodutide
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Lancet Diabetes Endocrinol 2024 300 Clinical Trial
Phase 2 trial: survodutide (GLP-1/glucagon dual agonist) demonstrated significant weight loss across dose levels in adults with obesity across 12 countries.